eFoodSafety.com Announces That The KonLin Letter Has Issued a Featured Stock Follow-up Report on EFoodSafety.com, Inc. in Its February 2007 Issue.25 Year Old Top Performing Independent Market Letter Calls Company a Ground Floor Opportunity with Explosive Growth Potential and Forecasts a Short-Term Target Stock Price of $2.00 SCOTTSDALE, Ariz. -- eFoodSafety.com, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :EFSF EFSF Earth Federation Space Force (Mobile Suit Gundam) ), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that The KonLin Letter issued a Featured Stock Follow-Up Report on eFoodSafety.com, Inc. in its February 2007 issue. The KonLin Letter reiterates its "Strong Buy" recommendation of EFSF stock. Konrad Kuhn, editor of The KonLin Letter, said that "the bulls smell blood, since according to Buyins.net (www.buyins.net), a short squeeze Short Squeeze A situation in which a lack of supply and an excess demand for a traded stock forces the price upward. Notes: Short squeezes occur more often in smaller cap stocks with small floats. could take place and a buying panic buying panic A period of rapidly rising stock prices on very high volume as investors, speculators, traders, and institutions attempt to establish investment positions without regard to price. could occur if the stock closes above $0.3620." Mr. Kuhn further commented in another section of the report, "Big Pharma buys out two kinds of companies, those that give it a huge competitive advantage and those that can take its edge away." The KonLin Letter states that EFSF is a ground floor opportunity with explosive growth potential and has already established positive fundamentals. The KonLin Letter, a 25-year-old investment advisory newsletter noted for its fundamental and technical analysis of individual stocks and market movements, does not accept compensation for its analyses of selected companies. The report includes a review of the latest developments of the Company, the Company's market position and potential advantages, along with fundamentals and statistics. Mr. Kuhn cited the following reasons for his February 2007 follow-up recommendation: * Highlighted OraPhyte[TM], a $100 billion solution to plant-parasitic nematodes. Company and USDA USDA, n.pr See United States Department of Agriculture. had jointly filed a patent application and are currently working together on finalizing a Licensing Agreement between the parties - multi-billion dollar market size. * Clinical study on Cinnergen[TM] diabetes product, which was a Double Blind Phase I study that met FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. guidelines and surpassed expectations. Major retailers are anticipated to begin distributing the product shortly. * Company reduced its issued and outstanding shares by 20% and has taken 30 million shares out of the float. * Knock-Out Technologies completed and tested Trimyacin[TM], a Tuberculosis product, Auromoxin[TM], a Malaria product, and Occusyn[TM], a Lyme Disease Lyme disease, a nonfatal bacterial infection that causes symptoms ranging from fever and headache to a painful swelling of the joints. The first American case of Lyme's characteristic rash was documented in 1970 and the disease was first identified in a cluster at product - all with favorable results. Further necessary testing is planned. * Company announced name PurEffect[TM] and secured trademark of anti-acne product and will be announcing celebrity spokesperson(s) shortly. Mr. Kuhn commented, "Patricia Gruden continues to do an excellent job at the helm of eFoodSafety, and in my opinion, she's not done yet. I believe the Cinnergen[TM] success will be followed by many other products. The recent announcement of its cholesterol product, Cinnechol[TM], to be distributed through the Company's already existing and growing distribution channels was an excellent strategic move. I expect the Knock-Out division, which I have always classified as the 'crown jewel' of the eFoodSafety, will have a few more pleasant surprises in store for investors shortly." "I've said it many times before and I'll continue to say it, never in my 25-year history as a newsletter writer and analyst, have I seen a Company with such dramatic upside potential Upside potential The amount by which analysts or investors expect the price of a security may increase. upside potential The potential price or gain that may be expected in a security or in a security average, generally stated as the dollar in so many different multi-billion dollar markets," further added Mr. Kuhn. Patricia Gruden, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of eFoodSafety.com, Inc., stated, "The Company is pleased that The KonLin Letter has elected to continue following eFoodSafety's progress this year. The KonLin Letter is a highly-respected, long-established, Small-Cap newsletter which receives no compensation from the companies reviewed whose forecasts, commentary, and opinions are arrived at based solely on its own analysis." About KonLin Research & Analysis Corp. The KonLin Letter, www.KonLin.com, chooses low-priced stocks to analyze, with an emphasis on emerging growth and special situations poised for explosive price appreciation. The KonLin Letter has constantly been one of the leading publications on Wall Street. It has been rated one of the best performing market letters in the nation, offering a unique service that each month recommends five low-priced selections, including a featured stock of the month. EFSF was the featured stock in the month of September 2005. About eFoodSafety.com, Inc. eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal germicidal /ger·mi·ci·dal/ (jer?mi-si´d'l) antimicrobial (1). germicidal destructive to pathogenic microorganisms. product, Citroxin (formerly named Big Six Plus) - EPA EPA eicosapentaenoic acid. EPA abbr. eicosapentaenoic acid EPA, n.pr See acid, eicosapentaenoic. EPA, n. Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria Listeria /Lis·te·ria/ (lis-ter´e-ah) a genus of gram-negative bacteria (family Corynebacterium); L. monocyto´genes causes listeriosis. Lis·te·ri·a n. , Pseudomonas Pseudomonas A genus of gram-negative, nonsporeforming, rod-shaped bacteria. Motile species possess polar flagella. They are strictly aerobic, but some members do respire anaerobically in the presence of nitrate. , Salmonella, Staphylococcus staphylococcus (stăf'ələkŏk`əs), any of the pathogenic bacteria, parasitic to humans, that belong to the genus Staphylococcus. The spherical bacterial cells (cocci) typically occur in irregular clusters [Gr. , and Streptococcus streptococcus (strĕp'təkŏk`əs), any of a group of gram-positive bacteria, genus Streptococcus, some of which cause disease. , Avian Influenza avian influenza: see influenza. , and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium clostridium Any of the rod-shaped, usually gram-positive bacteria (see gram stain) that make up the genus Clostridium. They are found in soil, water, and the intestinal tracts of humans and other animals. Some species grow only in the complete absence of oxygen. Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn[TM]-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn[TM] line. The Company is also owner of Cinnergen[TM], a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com) and Cinnechol[TM], a new multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect[TM] anti-acne skin care system. Please visit the Company's website at: http://www.efoodsafety.com. Safe Harbor Forward-Looking Statements Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion